What is the long-term trend for Edgewise Therapeutics, Inc.'s customer receivables and other?

Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s customer receivables and other has grown at a 176.8% compound annual growth rate (CAGR), from $402K to $23.61M.

Edgewise Therapeutics, Inc. EWTX Customer receivables and Other

Customer receivables and Other at other companies

Morgan StanleyMS

$2.52B+0.4%

Raymond James FinancialRJF

$1.81B-3.5%

Chicago Atlantic Real Estate FinanceREFI

$2.56M+388%

Customers BancorpCUBI

$2.37M+25.7%

Arbor Realty TrustABR

$35.25M+267%

Ares Management CorporationARES

$0-100%

Other financials

Income statement

See full

Operating income-$54.1M-17.7%

Net income-$49.0M-20.1%

EPS (diluted)-$0.46-7.0%

Balance sheet

See full

Cash & equivalents$33.2M-33.5%

Total debt$3.8M-16.8%

Total equity$493.2M+14.8%

Total assets$518.5M+14.1%

Cash flow

See full

Operating cash flow-$42.5M-12.4%

CapEx$260.0K+491%

Free cash flow-$42.8M-12.9%

Valuation

See full

Market cap$4.18B+61.3%

Returns & leverage

See full

Return on equity-38.1%+13.4pp

Debt / equity0×0.0×

Current ratio22.6×+1.6×

Where this comes from

Reported directly by Edgewise Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeOther.

The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Edgewise Therapeutics, Inc.'s customer receivables and other.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Edgewise Therapeutics, Inc.'s customer receivables and other?: Edgewise Therapeutics, Inc. (EWTX) reported customer receivables and other of $5.1M in Q1 2026.
How has Edgewise Therapeutics, Inc.'s customer receivables and other changed year-over-year?: Edgewise Therapeutics, Inc.'s customer receivables and other decreased by 1.1% year-over-year, from $5.16M to $5.1M.
What is the long-term trend for Edgewise Therapeutics, Inc.'s customer receivables and other?: Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s customer receivables and other has grown at a 176.8% compound annual growth rate (CAGR), from $402K to $23.61M.